Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAOLATE vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MAOLATE is a centrally acting muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is not fully understood, but it is thought to act via inhibition of polysynaptic reflexes at the spinal level and possibly through sedation.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
250 mg orally 4 times daily or 500 mg orally 3 times daily for 21 days; maximum daily dose 2000 mg.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment, up to 20-30 hours in severe renal failure; dose adjustment required for Cr Cl <30 m L/min)
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Hepatic metabolism via glucuronidation and oxidative pathways; CYP450 involvement not well characterized.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Renal: ~70% as unchanged drug and metabolites; Biliary/Fecal: ~30%
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
98% bound to albumin
30-35% bound to albumin.
0.15-0.25 L/kg, indicating limited extravascular distribution
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Oral: 75-85% (first-pass metabolism reduces absorption)
Oral: 70-85% with high variability; intrathecal: 100%.
GFR >= 50 m L/min: no adjustment; GFR 30-49 m L/min: 250 mg twice daily; GFR 10-29 m L/min: 250 mg once daily; GFR < 10 m L/min: 250 mg every 48 hours.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg once daily; Child-Pugh C: contraindicated.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Not established; safety and efficacy not determined in patients < 18 years.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
Start at lower end of dosing (250 mg twice daily) due to age-related renal impairment; monitor renal function.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
None.
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
May cause sedation and dizziness; caution with activities requiring alertness.,Use with caution in patients with hepatic or renal impairment.,Potential for abuse and dependence; use with caution in patients with history of substance abuse.,May impair ability to drive or operate machinery.
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Hypersensitivity to maolate or any component of the formulation.,Patients with porphyria.,Patients with acute intermittent porphyria.,Concomitant use with MAO inhibitors (potential for increased CNS depression).
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
Strict avoidance of tyramine-rich foods: aged cheeses (e.g., cheddar, blue cheese), cured meats (salami, pepperoni), fermented soy products (tofu, miso), sauerkraut, pickled fish, broad bean pods, yeast extracts, and tap beers. Avoid excessive caffeine. Tyramine can cause hypertensive crisis.
No specific food interactions. Avoid alcohol due to additive CNS depression.
MAOLATE (methocarbamol): No well-controlled studies in pregnant women. Animal studies show no teratogenic effects at doses up to 3 times the human dose. First trimester: Limited data; theoretical risk based on muscle relaxant properties. Second and third trimesters: Use only if clearly needed; may cause neonatal hypotonia and respiratory depression if used near term.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
Methocarbamol is excreted in human milk in small amounts. M/P ratio unknown. Caution advised; monitor infant for sedation, poor feeding, or hypotonia.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
Pregnancy increases volume of distribution and hepatic metabolism; may require dose reduction due to altered pharmacokinetics. Limited data; use lowest effective dose and monitor response. No specific dose adjustment recommendations available.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
MAOLATE is a pseudo-drug name; no established clinical data. For educational purposes, consider that any 'MAOLATE' would be a monoamine oxidase inhibitor (MAOI), requiring avoidance of tyramine-rich foods to prevent hypertensive crisis. Use with caution in patients with cardiovascular disease. Monitor for serotonin syndrome when combined with serotonergic drugs. Discontinue 2 weeks before elective surgery due to anesthesia interactions.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Avoid foods high in tyramine such as aged cheeses, cured meats, fermented products, and certain alcoholic beverages.,Do not take over-the-counter cold or allergy medications without consulting your doctor due to risk of severe interactions.,Report any sudden severe headache, palpitations, or chest pain immediately.,Never exceed the prescribed dose; missed doses should not be doubled.,Discontinue the drug 2 weeks before any planned surgery or dental procedure.,Do not start or stop any other medications without medical advice.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
No interactions on record
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAOLATE vs BACLOFEN, answered by our medical review team.
MAOLATE is a Muscle Relaxant that works by MAOLATE is a centrally acting muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is not fully understood, but it is thought to act via inhibition of polysynaptic reflexes at the spinal level and possibly through sedation.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAOLATE and BACLOFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAOLATE is: 250 mg orally 4 times daily or 500 mg orally 3 times daily for 21 days; maximum daily dose 2000 mg.. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAOLATE and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAOLATE is classified as Category C. MAOLATE (methocarbamol): No well-controlled studies in pregnant women. Animal studies show no teratogenic effects at doses up to 3 times the human dose. First trimester: Limited da. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.